References:
  1. Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). The American journal of cardiology. 2002;90(4):358-63.
  2. Ralapanawa U and Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J Epidemiol Glob Health. 2021 Jun; 11(2): 169–177.
  3. Doost Hosseiny A, Moloi S, Chandrasekhar J, et al. Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. Open Heart. 2016;3:e000405.
  4. Van ’t Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet (London, England). 1997;350(9078):615-9.
  5. Van ’t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97(23):2302-6.
  6. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101(5):570-80.
  7. Eisenberg PR, Ghigliotti G. Platelet-dependent and procoagulant mechanisms in arterial thrombosis. International Journal of Cardiology. 1999;68, Supplement 1:S3-S10.
  8. Zeymer U. The role of eptifibatide in patients undergoing percutaneous coronary intervention. Expert Opinion on Pharmacotherapy. 2007;8(8):1147-54.
  9. Borja Ibanez et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177.
  10. Jennifer S. Lawton. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–e114.
  11. De Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC, et al. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. American heart journal. 2001;141(4):592-8.
  12. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol. 2004;43(2):276-83.
  13. Shariati H, Sanei H, Pourmoghadas A, Salehizadeh L, Amirpour A. Immediate outcomes of eptifibatide therapy during intracoronary stent implantation. Advanced Biomedical Research. 2016;5:204.
  14. Topcu S, Karal H, Kaya A, Bakirci EM, Tanboga IH, Kurt M, et al. The safety and efficacy of 12 versus 24 hours of tirofiban infusion in patients undergoing primary percutaneous coronary intervention. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2015;21(8):783-9.
  15. Schneider DJ. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. British Journal of Clinical Pharmacology. 2011;72(4):672-82.
  16. Becker RC. Thrombosis and the role of the platelet. The American Journal of Cardiology. 1999;83(9, Supplement 1):3-6.
  17. Mehran R et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. A Consensus Report From the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747.
  18. Joshua M. Stolker et al. Repeat Revascularization After Contemporary Percutaneous Coronary Intervention. An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year. Circ Cardiovasc Interv. 2012;5:772-782.
  19. Montalescot G et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients’ data with long-term follow-up. European Heart Journal (2007) 28, 443–449.
  20. Kandzari DE et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004 Mar;147(3):457-62.
  21. Jeremias A et al. Impact of Abciximab on Mortality and Reinfarction in Patients with Acute ST-Segment Elevation Myocardial Infarction Treated with Primary Stenting. Catheterization and Cardiovascular Interventions. (2010) 75(6):895–902.
  22. Mehilli J et al. Abciximab in Patients with Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial. Circulation. 2009;119:1933-1940.
  23. Zeymer U et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J Am Coll Cardiol. 2010 Aug 3;56(6):463-9.
  24. Tcheng JE et al. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000 Dec 16;356(9247):2037-44.
  25. Mahmoudi M et al. Integrilin in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. J Interven Cardiol. 2011;24:351–356.
  26. Le May MR et al. Primary Percutaneous Coronary Angioplasty with and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Integrilin-Facilitated Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST). Circ Cardiovasc Intervent. 2009;2:330-338.
Table 1. Patients’ demographics and clinical characteristics.